About this event
In his talk, Dr. Böhmig will lay focus on available therapeutic strategies in late antibody-mediated rejection (ABMR). In a deepened discussion of the current literature, he will describe the results of recent systematic trials, such as TRITON, and BORTEJECT, and discuss innovative concepts, such as costimulation blockade, interleukin-6 antagonism and targeting CD38.
Immucor is a proud partner to thousands of laboratories & donor centers. We are focused on continued innovation in transfusion and transplantation diagnostics.
Share this event